Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ASCO Annual Meeting 2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

2024 ASCO Annual Meeting

Keep up to date with all the top stories and latest evidence with our hub page, including official congress videos and expert takeaways.
ADVANCED SEARCH
Log in
Top
Clinical and Translational Medicine
Published in: Clinical and Translational Medicine 1/2016

Open Access 01-12-2016 | Review

Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention

Authors: Ercole L. Cavalieri, Eleanor G. Rogan

Published in: Clinical and Translational Medicine | Issue 1/2016

Login to get access

Abstract

Estrogens can initiate cancer by reacting with DNA. Specific metabolites of endogenous estrogens, the catechol estrogen-3,4-quinones, react with DNA to form depurinating estrogen-DNA adducts. Loss of these adducts leaves apurinic sites in the DNA, generating mutations that can lead to the initiation of cancer. A variety of endogenous and exogenous factors can disrupt estrogen homeostasis, which is the normal balance between estrogen activating and protective enzymes. In fact, if estrogen metabolism becomes unbalanced and generates excessive catechol estrogen 3,4-quinones, formation of depurinating estrogen-DNA adducts increases and the risk of initiating cancer is greater. The levels of depurinating estrogen-DNA adducts are high in women diagnosed with breast cancer and those at high risk for the disease. High levels of depurinating estrogen-DNA adducts before the presence of breast cancer indicates that adduct formation is a critical factor in breast cancer initiation. Women with thyroid or ovarian cancer also have high levels of estrogen-DNA adducts, as do men with prostate cancer or non-Hodgkin lymphoma. Depurinating estrogen-DNA adducts are initiators of many prevalent types of human cancer. These findings and other discoveries led to the recognition that reducing the levels of estrogen-DNA adducts could prevent the initiation of human cancer. The dietary supplements N-acetylcysteine and resveratrol inhibit formation of estrogen-DNA adducts in cultured human breast cells and in women. These results suggest that the two supplements offer an approach to reducing the risk of developing various prevalent types of human cancer.
Literature
1.
Nandi S (1978) Role of hormones in mammary neoplasia. Cancer Res 38:4046–4049PubMed
2.
Lang R, Redmann U (1979) Non-mutagenicity of some sex hormones in the Ames salmonella/microsome mutagenicity test. Mutat Res 67:361–365PubMedCrossRef
3.
Drevon C, Piccoli C, Montesano R (1981) Mutagenicity assays of estrogenic hormones in mammalian cells. Mutat Res 89:83–90PubMedCrossRef
4.
Lang R, Reimann R (1993) Studies for a genotoxic potential of some endogenous and exogenous sex steroids. I. Communication: examination for the induction of gene mutations using the Ames Salmonella/microsome test and the HGPRT test in V79 cells. Environ Mol Mutagen 21:272–304PubMedCrossRef
5.
Li JJ (1993) Estrogen carcinogenesis in hamster tissues: update. Endocr Rev 14:94–95
6.
Furth J (1982) Hormones as etiological agents in neoplasia. In: Becker FF (ed) Cancer a comprehensive treatise, 1 Etiology: chemical and physical carcinogenesis. Cancer Plenum Press, New York, pp 89–134CrossRef
7.
Li JJ, Li SA (1990) Estrogen carcinogenesis in hamster tissues: a critical review. Endocr Rev 11:524–531PubMedCrossRef
8.
Nandi S, Guzman RC, Yang J (1995) Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci 92:3650–3657PubMedPubMedCentralCrossRef
9.
10.
Dickson RB, Stancel GM (2000) Estrogen receptor-mediated processes in normal and cancer cells. J Natl Cancer Inst Monogr. 27:135–145PubMedCrossRef
11.
Cavalieri EL, Rogan EG (2010) Depurinating estrogen-DNA adducts in the etiology and prevention of breast and other human cancers. Future Oncol 6:75–91PubMedPubMedCentralCrossRef
12.
Cavalieri E, Rogan E (2011) Unbalanced metabolism of endogenous estrogens in the etiology and prevention of human cancer. J Steroid Biochem Mol Biol 125:169–180PubMedPubMedCentralCrossRef
13.
14.
Cavalieri E, Rogan E (2014) The molecular etiology and prevention of estrogen-initiated cancers. Mol Aspects Med 36:1–55PubMedCrossRef
15.
Saeed M, Rogan E, Cavalieri E (2009) Mechanism of metabolic activation and DNA adduct formation by the human carcinogen diethylstilbestrol: the defining link to natural estrogens. Int J Cancer 124:1276–1284PubMedPubMedCentralCrossRef
16.
Cavalieri EL, Li K-M, Balu N, Saeed M, Devanesan P, Higginbotham S, Zhao J, Gross ML, Rogan E (2002) Catechol ortho-quinones: the electrophilic compounds that form depurinating DNA adducts and could initiate cancer and other diseases. Carcinogenesis 23:1071–1077PubMedCrossRef
17.
Zahid M, Saeed M, Rogan EG, Cavalieri EL (2010) Benzene and dopamine catechol quinones could initiate cancer or neurogenic disease. Free Radic Biol Med 48:318–324PubMedPubMedCentralCrossRef
18.
Saeed M, Higginbotham S, Rogan E, Cavalieri E (2007) Formation of depurinating N3adenine and N7guanine adducts after reaction of 1,2-naphthoquinone or enzyme-activated 1,2-dihydroxynaphthalene with DNA. Implications for the mechanism of tumor initiation by naphthalene. Chem Biol Interact 165:175–188PubMedCrossRef
19.
Saeed M, Higginbotham S, Gaikwad N, Chakravarti D, Rogan E, Cavalieri E (2009) Depurinating naphthalene-DNA adducts in mouse skin related to cancer initiation. Free Radic Biol Med 47:1075–1081PubMedPubMedCentralCrossRef
20.
Cavalieri EL, Stack DE, Devanesan PD, Todorovic R, Dwivedy I, Higginbotham S, Johansson SL, Patil KD, Gross ML, Gooden JK, Ramanathan R, Cerny RL, Rogan EG (1997) Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumor initiators. Proc Natl Acad Sci 94:10937–10942PubMedPubMedCentralCrossRef
21.
Dwivedy I, Devanesan P, Cremonesi P, Rogan E, Cavalieri E (1992) Synthesis and characterization of estrogen 2,3- and 3,4-quinones. Comparison of DNA adducts formed by the quinones versus horseradish peroxidase-activated catechol estrogens. Chem Res Toxicol 5:828–833PubMedCrossRef
22.
Li K-M, Todorovic R, Devanesan P, Higginbotham S, Köfeler H, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL (2004) Metabolism and DNA binding studies of 4-hydroxyestradiol and estradiol-3,4-quinone in vitro and in female ACI rat mammary gland in vivo. Carcinogenesis 25:289–297PubMedCrossRef
23.
Saeed M, Zahid M, Gunselman SJ, Rogan E, Cavalieri E (2005) Slow loss of deoxyribose from the N7deoxyguanosine adducts of estradiol-3,4-quinone and hexestrol-3′,4′-quinone. implications for mutagenic activity. Steroids. 70:29–35PubMedCrossRef
24.
Saeed M, Rogan E, Fernandez SV, Sheriff F, Russo J, Cavalieri E (2007) Formation of depurinating N3Adenine and N7Guanine adducts by MCF-10F cells cultured in the presence of 4-hydroxyestradiol. Int J Cancer 120:1821–1824PubMedCrossRef
25.
Stack D, Byun J, Gross ML, Rogan EG, Cavalieri E (1996) Molecular characteristics of catechol estrogen quinones in reactions with deoxyribonucleosides. Chem Res Toxicol 9:851–859PubMedCrossRef
26.
Zahid M, Kohli E, Saeed M, Rogan E, Cavalieri E (2006) The greater reactivity of estradiol-3,4-quinone versus estradiol-2,3-quinone with DNA in the formation of depurinating adducts. implications for tumor-initiating activity. Chem Res Toxicol 9:164–172CrossRef
27.
Hinrichs B, Zahid M, Saeed M, Ali MF, Cavalieri EL, Rogan EG (2011) Formation of diethylstilbestrol-DNA adducts in human breast epithelial cells and inhibition by resveratrol. J Steroid Biochem Mol Biol 127:276–281PubMedPubMedCentralCrossRef
28.
Jan S-T, Devanesan P, Stack D, Ramanathan R, Byun J, Gross ML, Rogan E, Cavalieri E (1998) Metabolic activation and formation of DNA adducts of hexestrol, a synthetic non-steroidal carcinogenic estrogen. Chem Res Toxicol 11:412–419PubMedCrossRef
29.
Saeed M, Gunselman SJ, Higginbotham S, Rogan E, Cavalieri E (2005) Formation of the depurinating N3adenine and N7guanine adducts by reaction of DNA with hexestrol-3′-4′-quinone or enzyme-activated 3′-hydroxyhexestrol. Implications for a unifying mechanism of tumor initiation by natural and synthetic estrogens. Steroids 70:37–45PubMedCrossRef
30.
31.
Rinsky RA, Smith AB, Hornung R, Filloon TG, Young RJ, Okun AH, Landrigan PJ (1987) Benzene and leukemia. An epidemiologic risk assessment. N Engl J Med 316:1044–1050PubMedCrossRef
32.
Sabourin PJ, Bechtold WE, Griffith WC, Birnbaum LS, Lucier G, Henderson RF (1989) Effect of exposure concentration, exposure rate, and route of administration on metabolism of benzene by F344 rats and B6C3F1 mice. Toxicol Appl Pharmacol 99:421–444PubMedCrossRef
33.
34.
Greenlee WF, Gross EA, Irons RD (1981) Relationship between benzene toxicity and the disposition of 14C-labelled benzene metabolites in the rat. Chem Biol Interact 33:285–299PubMedCrossRef
35.
Rickert DE, Baker TS, Bus JS, Barrow CS, Irons RD (1979) Benzene disposition in the rat after exposure by inhalation. Toxicol Appl Pharmacol 49:417–423PubMedCrossRef
36.
Sadler A, Subrahmanyam VV, Ross D (1988) Oxidation of catechol by horseradish peroxidase and human leukocyte peroxidase: reactions of o-benzoquinone and o-benzosemiquinone. Toxicol Appl Pharmacol 93:62–71PubMedCrossRef
37.
National Toxicology Program. Toxicology and Carcinogenesis Studies of Naphthalene (CAS No. 91-20-3). In: F344/N Rats (Inhalation Studies), NTP Technical Report No. 500. Research Triangle Park, NC: NIH Publ. No. 01-4434. 2000
38.
Herbst AL, Ulfelder H, Poskanzer DC (1971) Adenocarcinoma of the vagina. Association of maternal stilbestrol therapy with tumor appearance in young women. N Engl J Med 284:878–881PubMedCrossRef
39.
Li JJ, Li SA, Klicka JK, Parsons JA, Lam LK (1983) Relative carcinogenic activity of various synthetic and natural estrogens in the Syrian hamster kidney. Cancer Res 43:5200–5204PubMed
40.
Liehr JG, Ballatore AM, Dague BB, Ulubelen AA (1985) Carcinogenicity and metabolic activation of hexestrol. Chem Biol Interact 55:157–176PubMedCrossRef
41.
Metzler M, McLachlan JA (1981) Oxidative metabolism of the synthetic estrogens hexestrol and dienestrol indicates reactive intermediates. Adv Exp Med Biol. 136:829–837PubMed
42.
Haaf H, Metzler M (1985) In vitro metabolism of diethylstilbestrol by hepatic, renal and uterine microsomes of rats and hamsters.Effects of different inducers. Biochem Pharmacol. 34:3107–3115PubMedCrossRef
43.
Blaich G, Göttlicher M, Cikryt P, Metzler M (1990) Effects of various inducers on diethylstilbestrol metabolism, drug-metabolizing enzyme activities and the aromatic hydrocarbon (Ah) receptor in male Syrian golden hamster liver. J Steroid Biochem. 35:201–204PubMedCrossRef
44.
Zhu BT, Conney AH (1998) Functional role of estrogen metabolism in target cells: review and perspectives. Carcinogenesis 9:1–27CrossRef
45.
Spink DC, Hayes CL, Young NR, Christou M, Sutter TR, Jefcoate CR, Gierthy JF (1994) The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on estrogen metabolism in MCF-7 breast cancer cells: evidence for induction of a novel 17 beta-estradiol 4-hydroxylase. J Steroid Biochem Mol Biol 51:251–258PubMedCrossRef
46.
Hayes CL, Spink DC, Spink BC, Cao JQ, Walker NJ, Sutter TR (1996) 17β-Estradiol hydroxylation catalyzed by human cytochrome P450 1B1. Proc Natl Acad Sci USA 93:9776–9781PubMedPubMedCentralCrossRef
47.
Spink DC, Spink BC, Cao JQ, DePasquale JA, Pentecost BT, Fasco MJ, Li Y, Sutter TR (1998) Differential expression of CYP1A1 and CYP1B1 in human breast epithelial cells and breast tumor cells. Carcinogenesis 19:291–298PubMedCrossRef
48.
Männistö PT, Kaakkola S (1999) Catechol-O-methyltransferase (COMT): biochemistry, molecular biology, pharmacology, and clinical efficacy of the new selective COMT inhibitors. Pharmacol Rev 51:593–628PubMed
49.
50.
Kappus H (1985) Lipid peroxidation: Mechanisms, analysis, enzymology and biological relevance. In: Sies H (ed) Oxidative Stress. Academic Press, New York, pp 273–310CrossRef
51.
Gaikwad NW, Rogan EG, Cavalieri EL (2007) Evidence from ESI-MS for NQO1-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 43:1289–1298PubMedPubMedCentralCrossRef
52.
Gaikwad NW, Yang L, Rogan EG, Cavalieri EL (2009) Evidence from ESI-MS for NQO2-catalyzed reduction of estrogen ortho-quinones. Free Radic Biol Med 46:253–262PubMedPubMedCentralCrossRef
53.
Talalay P, Dinkova-Kostova AT, Holtzclaw WD (2003) Importance of phase 2 gene regulation in protection against electrophile and reactive oxygen toxicity and carcinogenesis. Adv Enzyme Regul 43:121–134PubMedCrossRef
54.
Cavalieri E, Saeed M, Zahid M, Cassada E, Snow D, Miljkovic M, Rogan E (2012) Mechanism of DNA depurination by carcinogens in relation to cancer initiation. IUBMB Life 64:169–179PubMedPubMedCentralCrossRef
55.
Pullman A, Pullman B (1981) Molecular electrostatic potential of the nucleic acids. Q Rev Biophys 14:289–380PubMedCrossRef
56.
Chakravarti D, Pelling JC, Cavalieri EL, Rogan EG (1995) Relating aromatic hydrocarbon-induced DNA adducts and H-ras mutations in mouse skin papillomas: the role of apurinic sites. Proc Natl Acad Sci USA 92:10422–10426PubMedPubMedCentralCrossRef
57.
Cavalieri E, Rogan E (1998) Mechanisms of tumor initiation by polycyclic aromatic hydrocarbons in mammals. In: Neilson AH (ed) The handbook of environmental chemistry, PAHs and related compounds. Springer-Verlag, Heidelberg, pp 81–117
58.
Devanesan PD, RamaKrishna NVS, Padmavathi NS, Higginbotham S, Rogan EG, Cavalieri EL, Marsch GA, Jankowiak R, Small GJ (1993) Identification and quantitation of 7,12-dimethylbenz[a]anthracene-DNA adducts formed in mouse skin. Chem Res Toxicol 6:364–371PubMedCrossRef
59.
Cavalieri EL, Rogan EG, Li KM, Todorovic R, Ariese F, Jankowiak R, Grubor N, Small GJ (2005) Identification and quantification of the depurinating DNA adducts formed in mouse skin treated with dibenzo[a, l]pyrene (DB[a, l]P), or its metabolites and in rat mammary gland treated with DB[a, l]P. Chem Res Toxicol 18:976–983PubMedCrossRef
60.
Todorovic R, Devanesan P, Rogan E, Cavalieri E (2005) Identification and quantification of stable DNA adducts of dibenzo[a, l]pyrene or its metabolites in vitro, and in mouse skin and rat mammary gland. Chem Res Toxicol 18:984–990PubMedCrossRef
61.
Rogan EG, Devanesan PD, RamaKrishna NV, Higginbotham S, Padmavathi NS, Chapman K, Cavalieri EL, Jeong H, Jankowiak R, Small GJ (1993) Identification and quantitation of benzo[a]pyrene–DNA adducts formed in mouse skin. Chem Res Toxicol 6:356–363PubMedCrossRef
62.
Colapietro AM, Goodell AL, Smart RL (1993) Characterization of benzo[a]pyrene-initiated mouse skin papillomas for Ha-ras mutations and protein kinase C levels. Carcinogenesis 14:2289–2295PubMedCrossRef
63.
Chakravarti D, Mailander P, Li KM, Higginbotham S, Zhang HL, Gross MS, Cavalieri E, Rogan E (2001) Evidence that a burst of DNA depurination in SENCAR mouse skin induces error-prone repair and forms mutations in the H-ras gene. Oncogene 20:7945–7953PubMedCrossRef
64.
Mailander PC, Meza JL, Higginbotham S, Chakravarti D (2006) Induction of A.T to G.C mutations by erroneous repair of depurinated DNA following estrogen treatment of the mammary gland of ACI rats. J Steroid Biochem Mol Biol 101:204–215PubMedCrossRef
65.
Bolton JL, Shen L (1998) p-Quinone methides are the major decomposition products of catechol estrogen o-quinones. Carcinogenesis 17:925–929CrossRef
66.
Liehr JG, Fang WF, Sirbasku DA, Ari-Ulubelen A (1986) Carcinogenicity of catechol estrogens in Syrian hamsters. J Steroid Biochem. 24:353–356PubMedCrossRef
67.
Li JJ, Li SA (1987) Estrogen carcinogenesis in Syrian hamster tissues: role of metabolism. Fed Proc. 46:1858–1863PubMed
68.
Newbold RR, Liehr JG (2000) Induction of uterine adenocarcinoma in CD-1 mice by catechol estrogens. Cancer Res 60:235–237PubMed
69.
Miller WR, O’Neill J (1987) The importance of local synthesis of estrogen within the breast. Steroids 50:537–548PubMedCrossRef
70.
Simpson ER, Mahendroo MS, Means GD, Kilgore MW, Hinshelwood MM, Graham-Lorence S, Amarneh B, Ito Y, Fisher CR, Michael MD et al (1994) Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocr Rev 15:342–355PubMed
71.
Jefcoate CR, Liehr JG, Santen RJ, Sutter TR, Yager JD, Yue W, Santner SJ, Tekmal R, Demers L, Pauley R, Naftolin F, Mor G, Berstein L (2000) Tissue-specific synthesis and oxidative metabolism of estrogens. In: Cavalieri E, Rogan E (eds) JNCI monograph 27: Estrogens as endogenous carcinogens in the Breast and Prostate. University Press, Oxford, pp 95–112
72.
Santner SJ, Feil PD, Santen RJ (1984) In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway. J Clin Endocrinol Metab 59:29–33PubMedCrossRef
73.
Pasqualini JR, Chetrite G, Blacker D, Feinstein MC, Delalonde L, Talbi M, Maloche C (1996) Concentrations of estrone, estradiol, and estrone sulfate and evaluation of sulfatase and aromatase activities in pre- and post-menopausal breast cancer patients. J Clin Endocrinol Metab 81:1460–1464PubMed
74.
Lu F, Zahid M, Saeed M, Cavalieri EL, Rogan EG (2007) Estrogen metabolism and formation of estrogen-DNA adducts in estradiol-treated MCF-10F cells. The effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin induction and catechol-O-methyltransferase inhibition. J Steroid Biochem Mol Biol 105:150–158PubMedPubMedCentralCrossRef
75.
Lu F, Zahid M, Wang C, Saeed M, Cavalieri EL, Rogan EG (2008) Resveratrol prevents estrogen-DNA adduct formation and neoplastic transformation in MCF-10F cells. Cancer Prev Res. 1:135–145CrossRef
76.
Mitrunen K, Hirvonen A (2003) Molecular epidemiology of sporadic breast cancer. The role of polymorphic genes involved in oestrogen biosynthesis and metabolism. Mutat Res 544:9–41PubMedCrossRef
77.
Singh S, Zahid M, Saeed M, Gaikwad NW, Meza JL, Cavalieri EL, Rogan EG, Chakravarti D (2009) NAD(P)H:quinone oxidoreductase 1 Arg139Trp and Pro187Ser polymorphism imbalance estrogen metabolism towards DNA adduct formation in human mammary epithelial cells. J Steroid Biochem Mol Biol 117:56–66PubMedPubMedCentralCrossRef
78.
Cavalieri EL, Devanesan P, Bosland MC, Badawi AF, Rogan EG (2002) Catechol estrogen metabolites and conjugates in different regions of the prostate of noble rats treated with 4-hydroxyestradiol: implications for estrogen-induced initiation of prostate cancer. Carcinogenesis 23:329–333PubMedCrossRef
79.
Cavalieri EL, Kumar S, Todorovic R, Higginbotham S, Badawi AF, Rogan EG (2001) Imbalance of estrogen homeostasis in kidney and liver of hamsters treated with estradiol: implications for estrogen-induced initiation of renal tumors. Chem Res Toxicol 14:1041–1050PubMedCrossRef
80.
Devanesan P, Santen RJ, Bocchinfuso WP, Korach KS, Rogan EG, Cavalieri EL (2001) Catechol estrogen metabolites and conjugates in mammary tumors and hyperplastic tissue from estrogen receptor alpha knock out (ERKO)/Wnt 1 mice; implications for initiation of mammary tumors. Carcinogenesis 22:1573–1576PubMedCrossRef
81.
Rogan EG, Badawi AF, Devanesan PD, Meza JL, Edney JA, West WW, Higginbotham SM, Cavalieri EL (2003) Relative imbalances in estrogen metabolism and conjugation in breast tissue of women with carcinoma: potential biomarkers of susceptibility to cancer. Carcinogenesis 24:697–702PubMedCrossRef
82.
Singh S, Chakravarti D, Edney JA, Hollins RR, Johnson PJ, West WW, Higginbotham SM, Cavalieri EL, Rogan EG (2005) Relative imbalances in the expression of estrogen-metabolizing enzymes in the breast tissue of women with breast carcinoma. Oncol Rep 14:1091–1096PubMed
83.
Gaikwad NW, Yang L, Muti P, Meza JL, Pruthi S, Ingle JN, Rogan EG, Cavalieri EL (2008) The molecular etiology of breast cancer: evidence from biomarkers of risk. Int J Cancer 122:1949–1957PubMedPubMedCentralCrossRef
84.
Gaikwad NW, Yang L, Pruthi S, Ingle JN, Sandhu N, Rogan E, Cavalieri E (2009) Urine biomarkers of risk in the molecular etiology of breast cancer. Breast Cancer Basic Clin Res 3:1–8
85.
Pruthi S, Yang L, Sandhu NP, Ingle JN, Beseler CL, Suman VJ, Cavalieri EL, Rogan EG (2012) Evaluation of serum estrogen-DNA adducts as potential biomarkers of breast cancer risk. J Steroid Biochem Mol Biol 132:73–79PubMedPubMedCentralCrossRef
86.
Gail MH, Brinton LA, Byar DP, Corle DK, Green SB, Schairer C, Mulvihill JJ (1989) Protective individualized probabilities of developing breast cancer for white females who are being examined annually. J Natl Cancer Inst 81:1879–1886PubMedCrossRef
87.
88.
Zahid M, Goldner W, Beseler CL, Rogan EG, Cavalieri EL (2013) Unbalanced estrogen metabolism in thyroid cancer. Int J Cancer 133:2642–2649PubMedPubMedCentral
89.
Yang L, Gaikwad N, Meza J, Cavalieri E, Muti P, Trock B, Rogan E (2009) Novel biomarkers for risk of prostate cancer-results from a case-control study. Prostate 69:41–48PubMedPubMedCentralCrossRef
90.
Gaikwad NW, Yang L, Weisenburger DD, Vose J, Beseler C, Rogan EG, Cavalieri E (2009) Urinary biomarkers suggest that estrogen-DNA adducts may play a role in the aetiology of non-Hodgkin lymphoma. Biomarkers 14:502–512PubMedPubMedCentralCrossRef
91.
Zahid M, Gaikwad N, Rogan EG, Cavalieri EL (2007) Inhibition of depurinating estrogen-DNA adducts formation by natural compounds. Chem Res Toxicol 20:1947–1953PubMedCrossRef
92.
De Flora S et al (1994) Mechanisms of anticarcinogenesis: The example of N-acetylcysteine. In: Ioannides C, Lewis DFV (eds) Drugs, diet and disease, mechanistic approaches to cancer. Prentice Hall, Herts, pp 151–202
93.
De Flora S, Cesarone CF, Balansky RM, Albini A, D’Agostini F, Bennicelli C, Bagnasco M, Camoirano A, Scatolini L, Rovida A, Izzotti A (1995) Chemopreventive properties and mechanisms of N-acetylcysteine. The experimental background. J Cell Biochem Suppl 22:33–41PubMedCrossRef
94.
Townsend DM, Tew KD, Tapiero H (2003) The importance of glutathione in human disease. Biomed Pharmacother 57:145–155PubMedCrossRef
95.
Cao K, Stack DE, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL (1998) Synthesis and structure elucidation of estrogen quinones conjugated with cysteine, N-acetylcysteine, and glutathione. Chem Res Toxicol 11:909–916PubMedCrossRef
96.
Cao K, Devanesan PD, Ramanathan R, Gross ML, Rogan EG, Cavalieri EL (1998) Covalent binding of catechol estrogens to glutathione catalyzed by horseradish peroxidase, lactoperoxidase, or rat liver microsomes. Chem Res Toxicol 11:917–924PubMedCrossRef
97.
Samuni AM, Chuang EY, Krishna MC, Stein W, DeGraff W, Russo A, Mitchell JB (2003) Semiquinone radical intermediate in catecholic estrogen-mediated cytotoxicity and mutagenesis: chemoprevention strategies with antioxidants. Proc Natl Acad Sci USA 100:5390–5395PubMedPubMedCentralCrossRef
98.
Zahid M, Saeed M, Ali MF, Rogan EG, Cavalieri EL (2010) N-acetylcysteine blocks formation of cancer-initiating estrogen-DNA adducts in cells. Free Radic Biol Med 49:392–400PubMedPubMedCentralCrossRef
99.
Venugopal D, Zahid M, Mailander PC, Meza JL, Rogan EG, Cavalieri EL, Chakravarti E (2008) Reduction of estrogen-induced transformation of mouse mammary epithelial cells by N-acetylcysteine. J Steroid Biochem Mol Biol 109:22–30PubMedPubMedCentralCrossRef
100.
Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, Fong HH, Farnsworth NR, Kinghorn AD, Mehta RG, Moon RC, Pezzuto JM (1997) Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 275:218–220PubMedCrossRef
101.
Aziz MH, Kumar R, Ahmad N (2003) Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms (review). Int J Oncol 23:17–28PubMed
102.
Stivala LA, Savio M, Carafoli F, Perucca P, Bianchi L, Maga G, Forti L, Pagnoni UM, Albini A, Prosperi E, Vannini V (2001) Specific structural determinants are responsible for the antioxidant activity and the cell cycle effects of resveratrol. J Biol Chem 276:22586–22594PubMedCrossRef
103.
Guengerich FP, Chunb YJ, Kima D, Gillam EMJ, Shimada T (2003) Cytochrome P450 1B1: a target for inhibition in anticarcinogenesis strategies. Mutat Res 523–524:173–182CrossRef
104.
Floreani M, Napoli E, Quintieri L, Palatini P (2003) Oral administration of trans-resveratrol to guinea pigs increases cardiac DT-diaphorase and catalase activities, and protects isolated atria from menadione toxicity. Life Sci 7224:2741–2750CrossRef
105.
Zahid M, Gaikwad NW, Ali MF, Saeed M, Yang L, Rogan EG, Cavalieri EL (2008) Prevention of estrogen-DNA adducts in MCF-10F cells by resveratrol. Free Radic Biol Med 45:136–145PubMedPubMedCentralCrossRef
106.
Zahid M, Saeed M, Beseler C, Rogan EG, Cavalieri EL (2011) Resveratrol and N-acetylcysteine block the cancer-initiating step in MCF-10F cells. Free Radic Biol Med 50:78–85PubMedPubMedCentralCrossRef
107.
Metadata
Title
Depurinating estrogen-DNA adducts, generators of cancer initiation: their minimization leads to cancer prevention
Authors
Ercole L. Cavalieri
Eleanor G. Rogan
Publication date
01-12-2016
Publisher
Springer Berlin Heidelberg
Published in
Clinical and Translational Medicine / Issue 1/2016
Electronic ISSN: 2001-1326
DOI
https://doi.org/10.1186/s40169-016-0088-3

Other articles of this Issue 1/2016

Clinical and Translational Medicine 1/2016 Go to the issue

Review

Does it make sense to target one tumor cell chemotactic factor or its receptor when several chemotactic axes are involved in metastasis of the same cancer?

Research

Targeting polo-like kinase 1, a regulator of p53, in the treatment of adrenocortical carcinoma

Research

A quantitative metabolomics profiling approach for the noninvasive assessment of liver histology in patients with chronic hepatitis C

Research

Pharmacokinetics of oseltamivir in infants under the age of 1 year

Review

Choices have consequences: the nexus between DNA repair pathways and genomic instability in cancer

Review

Horizontal transfer of RNA and proteins between cells by extracellular microvesicles: 14 years later